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Desensitisation of human blood platelets to the effects of I-0-alkyl-2-acetyl-sn-glyceryl-3-phosphoryl- 
choline (1-0-alkylAcGEPC) and palmityl-lysophosphatidate by pre-incubation with these agonists has no 
effect on the aggregatory or secretory responses to collagen but causes 30-40% inhibition of these 
responses to thrombin in aspirin-treated platelets. The effects of 1-0-alkylAcGEPC and palmitoyl-lyso- 
phosphatidate are not additive. The results are not consistent with the proposal that 1-0-alkylAcGEPC 
or lysophosphatidate are the mediators for the responses to collagen observed when prostaglandinendo- 
peroxide synthesis is prevented, although they may play some role in the responses to thrombin under these 
conditions. 
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1. INTRODUCTION 
The aggregatory and secretory response of 
human platelets to low concentrations of collagen 
is mediated largely by release of prostaglandin en- 
doperoxides and thromboxane A2 and secretion of 
the contents of the protein and amine storage 
granules; e.g., ADP. However, when the synthesis 
of prostaglandin endoperoxides and thromboxane 
AZ is prevented by blockade of cyclooxygenase, ag- 
gregatory and secretory responses can still be 
observed albeit at higher collagen concentrations 
[ 11. A similar situation can be c&served on stimula- 
tion of human platelets with thrombin except that 
this agonist can cause aggregation in the absence of 
secretion provided that exogenous fibrinogen is 
present in the system [2]. 
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Stimulation of human platelets with collagen or 
thrombin causes the synthesis of small amounts of 
1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine 
(AcGEPC) which is a potent platelet agonist [3]. It 
has been suggested that AcGEPC, and other pro- 
ducts formed by the breakdown of membrane 
phospholipids (e.g., lysophosphatidate) might 
mediate the responses of human platelets to col- 
lagen and thrombin which can be observed in the 
absence of prostaglandin endoperoxide and throm- 
boxane A2 synthesis [4]. Since no antagonists have 
been described for the receptors responsible for in- 
teraction with AcGEPC or lysophosphatidate, we 
have evaluated this postulate by examining the ef- 
fect of desensitisation to AcGEPC or lysophospha- 
tidate on the aggregatory and secretory responses 
to collagen and thrombin obtained in the absence 
of cyclooxygenase products. The results obtained 
demonstrate that neither AcGEPC nor lysophos- 
phatidate have any role in the response to collagen. 
However, they provide some evidence that both 
Published by Elsevier Science Publishers B. V. 
00145793/83/$3.00 0 1983 Federation of European Biochemical Societies 142 
Volume 162, number 1 FEBS LETTERS October 1983 
these substances may contribute to the response to 
thrombin or share common activation pathways 
with thrombin. 
2. METHODS 
Venous blood was obtained from healthy human 
volunteers who denied taking any drugs for the 
previous 14 days. The blood was immediately 
dispersed into l/lOth vol. acid-citrate-dextrose 
[5] as anticoagulant o give a final whole blood 
citrate concentration of 10 mM and pH 7.4. The 
sample was centrifuged at 20-22°C at 200 x g for 
18 min. Platelet-rich plasma was removed with a 
plastic Pasteur pipette into a tightly-stoppered 
plastic tube, then incubated for 10 min with 
0.1 mM acetylsalicylate (ASA) and stored at 37°C. 
ATP secretion and the aggregatory response were 
measured simultaneously in a Payton dual-channel 
lumiaggregometer (model 102 S) by addition of 
0.04 ml luciferin-luciferase reagent (LKB-Wallac) 
to 0.36 ml platelet-rich plasma. Aliquots of ASA- 
treated platelet-rich plasma were equilibrated at 
37°C for 2 min in the aggregometer before addi- 
tion of agonists and stirred at 700 rev./min. The 
extent of secretion was determined by comparison 
with the response observed to a standard amount 
of ATP (1 nmol) added as an internal standard im- 
mediately after completion 
response. Control experiments 
the response of the system 
O-5 nmol ATP. 
3. RESULTS 
of the secretory 
demonstrated that 
was linear over 
Initial studies demonstrated that prior incuba- 
tion with either I-0-alkyl AcGEPC or palmitoyl- 
lysophosphatidate at concentrations sufficient to 
give a small reversible aggregatory response but no 
secretion caused a decrease in the responsiveness of
the platelets to a subsequent addition of l-O- 
stearoyl-AcGEPC. However, the effects of these 
two agonists differ (fig.1). Prior incubation with 
I-0-alkyl AcGEPC causes primarily a decrease in 
the maximal extent of the response to a subsequent 
challenge with this agonist although the 
dose/response curve is also shifted somewhat to 
the right. In contrast prior incubation with 
0.1 mM palmitoyl-lysophosphatidate has no effect 
on the maximal extent of the response to l-O- 
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Fig.1. Effect of exposure to suboptimal concentrations 
of palmitoyl-lysophosphatidate (0) or 1-O-stearoyl- 
AcGEPC (A,o) on the aggregatory response to l-O- 
stearoyl-AcGEPC. Platelet-rich plasma was prepared 
and platelet aggregation monitored as in section 2. 
Aliquots (0.40 ml) of platelet-rich plasma were stirred 
for 3 min at 37°C in the absence of agonist (u), in the 
presence of 0.1 mM palmitoyl-lysophosphatidate (0) or 
in the presence of 4 nM (A) or 10 nM (0) l-O- 
palmitoyl-AcGEPC. The platelet-rich plasma was then 
challenged with I-0-stearoyl-AcGEPC at the doses as 
indicated. The experiments were performed in the 
presence of 30pM indomethacin which in control 
experiments caused complete inhibition of aggregation 
induced by 1 mM arachidonate. Similar results were 
obtained if the platelets were incubated with l-O- 
stearoyl-AcGEPC rather than I-0-palmitoyl-AcGEPC. 
stearoyl AcGEPC but causes a small shift to the 
right in the dose/response curve (fig.1). Under 
these conditions the response to a subsequent addi- 
tion of 0.2 mM palmitoyl-lysophosphatidate is 
completely abolished (not shown). An increase in 
the incubation time beyond 3 min at 37°C with 
either I-0-alkyl-AcGEPC or palmitoyl-lysophos- 
phatidate does not increase the extent of the effect 
on the response to I-0-stearoyl-AcGEPC. How- 
ever, if the platelets are pre-incubated with higher 
concentrations of 1-0-alkyl-AcGEPC (10 nM) the 
response to a subsequent addition of PM levels of 
this agonist is completely suppressed (fig.1). 
We then examined the effect of pre-incubation 
with these doses of I-0-stearoyl-AcGEPC and 
palmitoyl-lysophosphatidate on the responses to 
thrombin observed in the presence of 
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Fig.2. Effects of exposure to a sub-optimal concentra- 
tion of 1-0-stearoyl-AcGEPC (A) or palmitoyl-lyso- 
phosphatidate (B) on the aggregatory (o,o) and 
secretory (m, q ) responses of human platelets to 
thrombin in the presence of acetylsalicylate. Platelet-rich 
plasma was prepared and incubated with 0.1 mM acetyl- 
salicylate as in section 2. Aliquots (0.36 ml) of platelet- 
rich plasma were incubated with 0.04 ml luciferin-luci- 
ferase reagent for 1 min at 37’C. EitheQ.01 PM l-O- 
stearoyl AcGEPC (A) or 0.1 mM palmitoyl-lysophos- 
phatidate (B) were then added; the system stirred at 
37°C for a further 3 min; and the platelets then 
challenged with the concentrations of thrombin as 
indicated. The closed symbols indicate results obtained 
if no agonist was added prior to thrombin. The open 
symbols indicate the results obtained if 1-O-stearoyl- 
AcGEPC (A) or palmitoyl-lysophosphatidate (B) was 
added prior to thrombin. 
acetylsalicylate. Pre-incubation with either of these 
agonists has little effect on the aggregatory 
response to thrombin but causes a marked, 
although incomplete, depression of the maximal 
extent of the secretory response (fig.2). The slight 
difference in the dose/response curves in (A,B) 
reflects the use of different platelet preparations 
for the two experiments. The effects of pre-incu- 
bation with I-0-stearoyl-AcGEPC or palmitoyl- 
lysophosphatidate on the secretory response to 
thrombin are of similar magnitude (fig.2) but are 
not independent of each other since the extent of 
inhibition caused by pre-incubation with both 
these agonists added together at the same concen- 
trations as used in fig.2 is no greater than that of 
either agonist added alone (not shown). 
In contrast to the result obtained using thrombin 
(fig.2), pre-incubation with 1-0-stearoyl AcGEPC 
or palmitoyl-lysophosphatidate has no significant 
effect on either the aggregatory or the secretory 
responses induced by collagen in platelet-rich 
plasma which has been treated with acetylsalicylate 
(fig.3). 
4. DISCUSSION 
An endogenous mediator for a given cell type 
can be defined as a substance which itself can in- 
duce a response and which is generated on stimula- 
tion of that cell by another agonist. Two possible 
modes of action can be considered for such an en- 
dogenous mediator: 
(i) Either it may act entirely within the cell in 
which it is generated and hence is more cor- 
rectly considered as an intracellular second 
messenger; 
(ii) Or it may be released into the extracellular 
medium and stimulate other cells by interac- 
tion with plasma membrane receptors. 
For the platelet both of these possibilities have 
been explicitly - suggested for thromboxane A2 
]6,71. 
Stimulation of platelets with either collagen or 
thrombin causes production by these cells of l-O- 
alkyl-AcGEPC [4] and lysophosphatidate [8] as 
well as of PGG2, PGHz and thromboxane AZ if the 
studies are performed in the absence of an in- 
hibitor of cyclooxygenase [9]. The role of the 
arachidonate metabolites as endogenous mediators 
in the responses to collagen and thrombin is well 
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established but that of I-0-alkyl-AcGEPC and 
lysophosphatidate has not been clarified. These 
studies indicate that since responsiveness of human 
platelets to collagen is unaffected by pre- 
incubation with 1-0-stearoyl-AcGEPC or 
lysophosphatidate (fig.3) neither of these agonists 
is involved as mediators of the aggregatory and 
secretory responses to collagen which are observed 
in the presence of aspirin and which cannot 
therefore be explained on the basis of arachidonate 
metabolite formation. 
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Fig.3. Effect of exposure to a sub-optimal concentration 
of 1-O-stearoyl-AcGEPC (A) or palmitoyl-lysophos- 
phatidate (B) on the aggregatory (0.0) and secretory 
(m, q ) responses of human platelets to collagen in the 
presence of acetylsalicylate. The experiments were 
performed and the data analysed and presented as for 
fig.2 except that the platelets were challenged with 
collagen at the concentrations as indicated. 
However, in the case of thrombin, partial 
(30-409’0) inhibition of the maximal secretory 
response together with some reduction in the ex- 
tent of the aggregatory response results from pre- 
incubation with doses of either 1-O-stearoyl- 
AcGEPC or of palmitoyl-lysophosphatidate (fig.2) 
which cause complete suppression of respon- 
siveness to a subsequent challenge to these latter 
agonists. Thus production of 1-0-alkyl-AcGEPC 
and lysophosphatidate may play some role in 
mediating the aggregatory and secretory responses 
to thrombin which are observed in the absence of 
cyclooxygenase product formation although the 
responses cannot be completely explained by pro- 
duction of these two mediators. Furthermore, the 
effects of pre-incubation with 1-0-alkyl-AcGEPC 
or lysophosphatidate on the responses to thrombin 
are not additive and hence cannot be attributed 
directly to occupancy of the unique receptors for 
these agonists, which appear to be present based 
on our data (fig. 1) and on [IO]. The mechanisms 
responsible for mediating the aggregatory response 
to I-0-alkyl-AcGEPC and lysophosphatidate ap- 
pear to interact at some point since desensitisation 
to lysophosphatidate clearly decreases respon- 
siveness to I-0-stearoyl-AcGEPC (fig. 1). Thus, 
the effect observed in fig.2 may be caused by some 
intracellular interaction between the mechanisms 
involved in inducing the responses to thrombin, 
1-0-alkyl-AcGEPC and lysophosphatidate, but 
not to collagen, rather than to the action of l-O- 
alkyl-AcGEPC and lysophosphatidate as en- 
dogenous mediators in the response to thrombin. 
Thrombin and I-0-alkyl-AcGEPC cause rapid 
increases in the cytoplasmic free Ca2+ concentra- 
tion, [Ca*+]i, whereas collagen fails to cause such 
a response unless the formation of cyclooxygenase 
products is permitted [ 1 l-131. The rapid rise in 
[Ca2+]i s transient on stimulation with AcGEPC 
and does not occur in response to a second addi- 
tion of this agonist [12]. Therefore, a possible ex- 
planation is that a subsequent [Ca2+]i response to 
thrombin might also be suppressed following ex- 
posure to AcGEPC. This is in fact not the case. An 
increase in [Ca’+]i to thrombin is not affected by 
desensitisation to AcGEPC (unpublished). 
In human platelets the production of en- 
dogenous mediators resulting from stimulation by 
collagen or thrombin provides a means by which 
positive feedback can occur to enhance the rate 
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and extent of responses to low concentrations of 
these agonists. Their production does not explain 
the responses observed at higher collagen or 
thrombin concentrations which are more likely to 
be due to enhanced levels of intracellular second 
messengers uch as Ca2+ and/or diacylglycerol 
produced as a direct consequence of the interaction 
of the cell with collagen or thrombin. 
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